New weekly shot aims to boost growth in babies with dwarfism
NCT ID NCT06079398
First seen Jan 11, 2026 · Last updated May 12, 2026 · Updated 13 times
Summary
This study tests a weekly injection called TransCon CNP in infants under 2 years old with achondroplasia, the most common form of dwarfism. The goal is to see if it safely improves growth compared to a placebo. About 72 babies will take part, receiving either the drug or a dummy shot for 52 weeks, followed by an open-label period where everyone gets the drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ascendis Investigational Site
RECRUITINGSaint Paul, Minnesota, 55102, United States
-
Ascendis Investigational Site
RECRUITINGHouston, Texas, 77030, United States
-
Ascendis Investigational Site
RECRUITINGMadison, Wisconsin, 53705, United States
-
Ascendis Investigational Site
RECRUITINGParkville, 3052, Australia
-
Ascendis Investigational Site
RECRUITINGLinz, 4020, Austria
-
Ascendis Investigational Site
RECRUITINGMontreal, H3T 1C5, Canada
-
Ascendis Investigational Site
RECRUITINGCopenhagen, 2100, Denmark
-
Ascendis Investigational Site
RECRUITINGHelsinki, 00029, Finland
-
Ascendis Investigational Site
RECRUITINGParis, 75743, France
-
Ascendis Investigational Site
RECRUITINGBerlin, 13353, Germany
-
Ascendis Investigational Site
RECRUITINGCologne, 50931, Germany
-
Ascendis Investigational Site
RECRUITINGDublin, D01 YC76, Ireland
-
Ascendis Investigational Site
RECRUITINGMilan, 20132, Italy
-
Ascendis Investigational Site
RECRUITINGAuckland, 1023, New Zealand
-
Ascendis Investigational Site
RECRUITINGOslo, 0372, Norway
-
Ascendis Investigational Site
RECRUITINGCoimbra, 3000-602, Portugal
-
Ascendis Investigational Site
RECRUITINGStockholm, 17176, Sweden
-
Ascendis Investigational Site
RECRUITINGLondon, SE1 7EH, United Kingdom
Conditions
Explore the condition pages connected to this study.